Research & Literature

Diagnosis of monoclonal gammopathy of renal significance.

Bridoux F, Leung N, Hutchison CA, et al.

Kidney international 2015; (87(4)):698-711 doi:10.1038/ki.2014.408.

Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients.

Chauvet S, Bridoux F, Ecotière L, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2015; (66(5)):756-67.

Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.

Cohen C, Royer B, Javaugue V, et al.

Kidney international 2015; (88(5)):1135-43 doi:10.1038/ki.2015.201.

Clinicopathological characteristics and outcomes of light chain deposition disease: an analysis of 48 patients in a single Chinese center.

Li XM, Rui HC, Liang DD, et al.

Annals of hematology 2016; (95(6)):901-9 doi:10.1007/s00277-016-2659-1.

[Randall-type monoclonal immunoglobulin deposition disease: From diagnosis to treatment].

Cohen C, Javaugue V, Joly F, et al.

Nephrologie & therapeutique 2016; (12(3)):131-9.

Outcomes of patients with renal monoclonal immunoglobulin deposition disease.

Kourelis TV, Nasr SH, Dispenzieri A, et al.

American journal of hematology 2016; (91(11)):1123-1128 doi:10.1002/ajh.24528.

Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management.

Bridoux F, Javaugue V, Bender S, et al.

Kidney international 2017; (91(2)):423-434 doi:10.1016/j.kint.2016.09.004.

Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio.

Singh G

Journal of clinical medicine research 2017; (9(1)):46-57 doi:10.14740/jocmr2802w.

Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.

Ziogas DC, Kastritis E, Terpos E, et al.

Leukemia & lymphoma 2017; (58(8)):1832-1839 doi:10.1080/10428194.2016.1267349.

[Light-chain deposition disease is a hematologic problem].

Rekhtina IG, Mendeleeva LP, Biryukova LS

Terapevticheskii arkhiv 2017; (89(1)):38-42 doi:10.17116/terarkh201789138-42.

Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.

Mohan M, Buros A, Mathur P, et al.

American journal of hematology 2017; (92(8)):739-745 doi:10.1002/ajh.24756.

Long-term renal survival of γ3-heavy chain deposition disease: a case report.

Katsuno T, Mizuno S, Mabuchi M, et al.

BMC nephrology 2017; (18(1)):239 doi:10.1186/s12882-017-0645-z.

High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.

Batalini F, Econimo L, Quillen K, et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2018; (24(1)):127-132 doi:10.1016/j.bbmt.2017.08.031.

Acquired Cutis Laxa Associated with Light and Heavy Chain Deposition Disease.

Majithia RA, George L, Thomas M, Fouzia NA

Indian dermatology online journal 2018; (9(1)):44-46 doi:10.4103/idoj.IDOJ_403_16.

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.

Gavriatopoulou M, Musto P, Caers J, et al.

Leukemia 2018; (32(9)):1883-1898 doi:10.1038/s41375-018-0209-7.

The heart in m.3243A>G carriers.

Finsterer J, Zarrouk-Mahjoub S

Herz 2020; (45(4)):356-361 doi:10.1007/s00059-018-4739-6.

The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Leung N, Bridoux F, Batuman V, et al.

Nature reviews. Nephrology 2019; (15(1)):45-59 doi:10.1038/s41581-018-0077-4.

Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study.

Joly F, Cohen C, Javaugue V, et al.

Blood 2019; (133(6)):576-587 doi:10.1182/blood-2018-09-872028.

Heavy Chain Deposition Disease: Clinicopathologic Characteristics of a Chinese Case Series.

Zhang Y, Li X, Liang D, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2020; (75(5)):736-743 doi:10.1053/j.ajkd.2019.08.013.

Epidemiological and clinical characteristics and outcome of monoclonal gammopathy of renal significance-related lesions in Latin America.

Peña C, Schutz NP, Riva E, et al.

Nephrology (Carlton, Vic.) 2020; (25(6)):442-449 doi:10.1111/nep.13685.

The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease.

Angel-Korman A, Stern L, Angel Y, et al.

Kidney international reports 2020; (5(4)):485-493 doi:10.1016/j.ekir.2020.01.011.

Heavy chain deposition disease presenting with raised anti-GBM antibody levels; a case report.

Turner M, Crawford A, Winterbottom C, et al.

BMC nephrology 2020; (21(1)):175 doi:10.1186/s12882-020-01837-2.

Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance.

Kastritis E, Theodorakakou F, Roussou M, et al.

British journal of haematology 2021; (193(1)):113-118 doi:10.1111/bjh.17052.

Understanding Mesangial Pathobiology in AL-Amyloidosis and Monoclonal Ig Light Chain Deposition Disease.

Herrera GA, Teng J, Turbat-Herrera EA, et al.

Kidney international reports 2020; (5(11)):1870-1893 doi:10.1016/j.ekir.2020.07.013.

Randall-Type Monoclonal Immunoglobulin Deposition Disease: New Insights into the Pathogenesis, Diagnosis and Management.

Cohen C, Joly F, Sibille A, et al.

Diagnostics (Basel, Switzerland) 2021; (11(3)) doi:10.3390/diagnostics11030420.

Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)-Associated Lesions: A Case Series.

Heybeli C, Alexander MP, Bentall AJ, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2022; (79(2)):202-216 doi:10.1053/j.ajkd.2021.04.015.

The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis.

Said SM, Best Rocha A, Valeri AM, et al.

Kidney international 2022; (101(1)):152-163 doi:10.1016/j.kint.2021.10.019.

Light chain deposition disease masquerading as smoking-associated nodular glomerulosclerosis with deposits identified by electron microscopy only.

Alom MS, Grewal R, Passero FC, et al.

CEN case reports 2022; (11(4)):448-452 doi:10.1007/s13730-022-00698-y.

Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance.

Sprangers B, Hegenbart U, Wetzels JFM

Transplantation 2023; (107(5)):1056-1068 doi:10.1097/TP.0000000000004443.

Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach.

Pianko MJ, Tiutan T, Derkach A, et al.

American journal of hematology 2023; (98(3)):421-431 doi:10.1002/ajh.26801.

Bilateral deafness, diabetes, and different types of cardiomyopathy in family members with m.3243A > g mutation: a case report.

Seiler F, Ruile P, Moser M, Helbing T

European heart journal. Case reports 2023; (7(2)):ytad073 doi:10.1093/ehjcr/ytad073.

The Role of Bone Marrow Biopsy Evaluation in the Workup for Monoclonal Gammopathy of Renal Significance: A Diagnosis of Exclusion.

Metcalf BD, Huang J, Kanaan HD, et al.

Archives of pathology & laboratory medicine 2024; (148(3)):e57-e62 doi:10.5858/arpa.2022-0342-OA.

Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Garderet L, Gras L, Koster L, et al.

Haematologica 2024; (109(8)):2619-2627 doi:10.3324/haematol.2023.284520.

Clinicopathological Characteristics of Light and Heavy Chain Deposition Disease: A Case Series.

Wang Y, Chen D, Hu R, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2024; (84(4)):447-456.e1 doi:10.1053/j.ajkd.2024.03.021.

Long-term renal survival of γ3-heavy-chain deposition disease complicated by heart failure: A case report.

Shi S, He K, Liang Y, Yue S

Clinical case reports 2024; (12(7)):e9091 doi:10.1002/ccr3.9091.

Diagnosis of light‑chain deposition disease after renal transplantation: A case report and literature review.

Yue J, Xu F, Zhang Y, et al.

Experimental and therapeutic medicine 2024; (28(3)):339 doi:10.3892/etm.2024.12628.

Paraprotein-Mediated Glomerular Diseases.

Miao J, Herrmann SM, Obaidi Z, et al.

Advances in kidney disease and health 2024; (31(4)):358-373 doi:10.1053/j.akdh.2024.02.005.

Translocation (11;14) is a common cytogenetic abnormality in clonal plasma cells in monoclonal immunoglobulin deposition disease.

Bhutani D, Liu Y, Chakraborty R, et al.

British journal of haematology 2024; (205(5)):1860-1865 doi:10.1111/bjh.19748.

Cytogenetic abnormality in non-systemic light chain amyloidosis monoclonal gammopathy of renal significance: A field needs to be explored.

Huang X

British journal of haematology 2024; (205(5)):1677-1678 doi:10.1111/bjh.19768.

Hemato-Renal Profile of Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits.

Johny J, John EE, Roy S, et al.

Indian journal of nephrology 2024; (35()):355-367 doi:10.25259/ijn_489_23.

Clinical and Pathological Characteristics of Non-AL Amyloidosis MGRS: A Single-Center Experience Over 10 Years.

Nie C, Lee H, Cheema K, et al.

Canadian journal of kidney health and disease 2025; (12()):20543581251318830 doi:10.1177/20543581251318830.

Classical complement activation in light and heavy chain deposition disease with acquired cutis laxa and bronchiolitis obliterans: a case report of monoclonal gammopathy of clinical significance.

Chen Y, Fan Y, Yang S, et al.

Frontiers in immunology 2025; (16()):1718342 doi:10.3389/fimmu.2025.1718342.

From confusion to diagnosis: a rare case of melas syndrome in a patient with familial consanguinity, recurrent stroke-like episodes, and concurrent FSGS.

Mohsen M, Juma S, Saleh D, et al.

BMC neurology 2026; (26(1)).

Systematic Review of Kidney Transplant Outcomes in Monoclonal Ig Deposition Disease.

Heybeli C, Leung N

Kidney international reports 2026; (11(5)):106372 doi:10.1016/j.ekir.2026.106372.

Comparison of bortezomib with dexamethasone and thalidomide with dexamethasone in the treatment of patients with monoclonal immunoglobulin deposition disease.

Jiang J, Chen W, Wu X, et al.

Journal of nephrology 2026; doi:10.1093/joneph/aajag144.

Hematologic response assessment in monoclonal gammopathy of renal significance: critical appraisal of current criteria.

Domingo-González A, Cannata-Ortiz P, Fernández-Prado R, et al.

Frontiers in medicine 2026; (13()):1902202 doi:10.3389/fmed.2026.1902202.